Halozyme Therapeutics Inc (HALO)
44.71
-0.68
(-1.50%)
USD |
NASDAQ |
May 17, 16:00
44.73
+0.02
(+0.04%)
Pre-Market: 20:00
Halozyme Therapeutics Enterprise Value: 6.728B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 6.728B |
| May 16, 2024 | 6.814B |
| May 15, 2024 | 6.869B |
| May 14, 2024 | 6.615B |
| May 13, 2024 | 6.588B |
| May 10, 2024 | 6.529B |
| May 09, 2024 | 6.617B |
| May 08, 2024 | 6.384B |
| May 07, 2024 | 6.282B |
| May 06, 2024 | 6.238B |
| May 03, 2024 | 6.117B |
| May 02, 2024 | 6.105B |
| May 01, 2024 | 6.039B |
| April 30, 2024 | 5.887B |
| April 29, 2024 | 5.968B |
| April 26, 2024 | 5.943B |
| April 25, 2024 | 5.929B |
| April 24, 2024 | 6.013B |
| April 23, 2024 | 5.994B |
| April 22, 2024 | 5.961B |
| April 19, 2024 | 5.952B |
| April 18, 2024 | 5.846B |
| April 17, 2024 | 5.873B |
| April 16, 2024 | 5.919B |
| April 15, 2024 | 5.962B |
| Date | Value |
|---|---|
| April 12, 2024 | 5.948B |
| April 11, 2024 | 6.038B |
| April 10, 2024 | 6.033B |
| April 09, 2024 | 6.141B |
| April 08, 2024 | 6.113B |
| April 05, 2024 | 6.261B |
| April 04, 2024 | 6.091B |
| April 03, 2024 | 6.154B |
| April 02, 2024 | 6.180B |
| April 01, 2024 | 6.293B |
| March 31, 2024 | 6.211B |
| March 28, 2024 | 6.332B |
| March 27, 2024 | 6.338B |
| March 26, 2024 | 6.256B |
| March 25, 2024 | 6.299B |
| March 22, 2024 | 6.256B |
| March 21, 2024 | 6.273B |
| March 20, 2024 | 6.294B |
| March 19, 2024 | 6.348B |
| March 18, 2024 | 6.292B |
| March 15, 2024 | 6.355B |
| March 14, 2024 | 6.346B |
| March 13, 2024 | 6.417B |
| March 12, 2024 | 6.493B |
| March 11, 2024 | 6.398B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.900B
Minimum
Mar 18 2020
9.276B
Maximum
Dec 02 2022
5.268B
Average
5.744B
Median
Enterprise Value Benchmarks
| Novavax Inc | 1.604B |
| Globus Medical Inc | 8.687B |
| Denali Therapeutics Inc | 1.988B |
| AIM ImmunoTech Inc | 7.729M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 76.82M |
| Revenue (Quarterly) | 195.88M |
| Total Expenses (Quarterly) | 100.34M |
| EPS Diluted (Quarterly) | 0.60 |
| Gross Profit Margin (Quarterly) | 85.54% |
| Profit Margin (Quarterly) | 39.22% |
| Earnings Yield | 5.41% |
| Operating Earnings Yield | 6.43% |
| Normalized Earnings Yield | 4.983 |